Positive News SentimentPositive NewsNASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $6.18 -0.21 (-3.29%) Closing price 04:00 PM EasternExtended Trading$6.24 +0.07 (+1.05%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcturus Therapeutics Stock (NASDAQ:ARCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcturus Therapeutics alerts:Sign Up Key Stats Today's Range$5.97▼$6.4550-Day Range$6.37▼$9.2252-Week Range$5.85▼$24.17Volume707,529 shsAverage Volume476,172 shsMarket Capitalization$175.64 millionP/E RatioN/ADividend YieldN/APrice Target$24.25Consensus RatingModerate Buy Company Overview Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases. The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore. Additional preclinical programs are directed toward addressing other metabolic disorders and infectious diseases. Arcturus’s research and development efforts focus on leveraging mRNA’s capacity for rapid design and production, aiming to reduce development timelines compared with traditional biologics. Headquartered in San Diego, California, Arcturus maintains research and manufacturing facilities both in the United States and in Singapore, reflecting its commitment to global collaboration and supply chain resilience. The Singapore facility supports the company’s vaccine development programs and provides clinical-scale manufacturing capabilities to meet regulatory requirements in multiple jurisdictions. Since going public in 2018, Arcturus has been led by Chief Executive Officer Joseph E. Payne, who brings experience from several biotechnology and pharmaceutical roles. Under his leadership, the company has forged partnerships with academic institutions and contract manufacturing organizations to advance its clinical programs. Arcturus continues to explore new applications of its mRNA platform through collaborations and licensing agreements aimed at expanding its pipeline and demonstrating the versatility of mRNA-based therapeutics.AI Generated. May Contain Errors. Read More Arcturus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreARCT MarketRank™: Arcturus Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 1071st out of 1,704 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingArcturus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArcturus Therapeutics has a consensus price target of $24.25, representing about 293.3% upside from its current price of $6.17.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.99) to ($3.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.11% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 15.47, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently increased by 1.39%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment1.86 News SentimentArcturus Therapeutics has a news sentiment score of 1.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search Interest8 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARCT Stock News HeadlinesArcturus Therapeutics (NASDAQ:ARCT) Share Price Crosses Below 50-Day Moving Average - Time to Sell?July 8, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH) and Arcturus Therapeutics (ARCT)July 3, 2026 | theglobeandmail.comJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI breakthrough they call 'M.A.G.I.' will collide with a rare market pattern by July 30. That pattern carries a 100% historical track record. The last time it triggered, early investors had a chance to turn $10,000 into as much as $350,000 in roughly 12 months.July 16 at 1:00 AM | Brownstone Research (Ad)Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trialJuly 3, 2026 | finance.yahoo.comArcturus Therapeutics Shares Rise on Plans to Work with Thermo Fisher Scientific on Cystic Fibrosis DrugJuly 2, 2026 | marketwatch.comArcturus Picks Thermo Fisher To Support Cystic Fibrosis TherapyJuly 2, 2026 | benzinga.comArcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic FibrosisJuly 2, 2026 | businesswire.comArcturus could halve the grid's electrical losses using its nano-infused copperJune 30, 2026 | techcrunch.comTSee More Headlines ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $6.13 on January 1st, 2026. Since then, ARCT shares have increased by 0.6% and is now trading at $6.1660. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Friday, May, 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.08. The biotechnology company earned $2.06 million during the quarter, compared to analysts' expectations of $6.30 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 36.55% and a negative net margin of 143.80%. Read the conference call transcript. Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' top institutional investors include Hennion & Walsh Asset Management Inc. (1.22%). View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings5/08/2026Today7/16/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ARCT's financial health is in the Red zone, according to TradeSmith. ARCT has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARCT CIK1768224 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year Founded2013Price Target and Rating Average Price Target for Arcturus Therapeutics$24.25 High Price Target$54.00 Low Price Target$9.00 Potential Upside/Downside+292.4%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.78 million Net Margins-143.80% Pretax Margin-143.80% Return on Equity-36.55% Return on Assets-28.40% Debt Debt-to-Equity RatioN/A Current Ratio6.31 Quick Ratio6.31 Sales & Book Value Annual Sales$82.03 million Price / Sales2.14 Cash FlowN/A Price / Cash FlowN/A Book Value$7.53 per share Price / Book0.82Miscellaneous Outstanding Shares28,420,000Free Float23,364,000Market Cap$175.64 million OptionableOptionable Beta2.37 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ARCT) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersThe Lithium Gold Rush Minted A New $1B UnicornThe Lithium Gold Rush Minted A New $1B Unicorn This lithium producer surpassed a $1B private valuation, joi...EnergyX | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
